https://pidnarulexinhibitor.co....m/treating-focus-def
Patients got 500 to 1000 mg of intravenous rituximab every 6 months until 18 months. Relapse rate each year and expanded impairment condition scale (EDSS) had been obtained at standard and through the post treatment follow-up. An overall total of 70 RRMS patients with the mean age 40.25 ± 8.17 were examined. At standard, the mean of EDSS and relapse price was 5.3 ± 1.08 and 0.95 ± 0.64, respectively. After 18 months therapy with rituximab, the relapse prices had been dramatically reduce
Like
Comment
Share
